Assess whether a CMC change is a comparability or a new product (61604e)

Situation

In a mid-size sponsor after a complete response letter, advisory-committee question list that exposes a weak secondary endpoint is the evidence after a pediatric ethicist objecting to the proposed design. Pharmacovigilance medical reviewer has to pick A CMC change is a comparability or A new product for this Pharma & Life Sciences CMC and Development Pathways close using advisory-committee question list that exposes a weak secondary endpoint.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Advisory-committee question list that exposes a weak secondary endpoint reads as A CMC change is a comparability once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population.
• Advisory-committee question list that exposes a weak secondary endpoint is closer to A new product after a pediatric ethicist objecting to the proposed design; A CMC change is a comparability would over-claim this CMC and Development Pathways extract.
• A dual reading is still live in advisory-committee question list that exposes a weak secondary endpoint for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.
• Advisory-committee question list that exposes a weak secondary endpoint is missing the fact pharmacovigilance medical reviewer needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a pediatric ethicist objecting to the proposed design and write the one fact that would move a CMC change is for pharmacovigilance medical reviewer.